Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Clinical Neurology
Reference10 articles.
1. Toyka, K. V. et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296, 125–131 (1977).
2. Gilhus, N. E. et al. Myasthenia gravis. Nat. Rev. Dis. Primers 5, 30 (2019).
3. Dalakas, M. C. Immunotherapy in myasthenia gravis in the era of biologics. Nat. Rev Neurol. 15, 113–124 (2019).
4. Howard, J. F. Jr et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526–536 (2021).
5. argenx. argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis. argenx https://www.argenx.com/news/argenx-announces-fda-acceptance-bla-filing-efgartigimod-treatment-generalized-myasthenia (2021).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献